Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni Syndrome-Reference-Cited by-同舟云学术

Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni Syndrome

Published:2024-06 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Bottosso Michele¹²^ORCID,Verret Benjamin¹³,Caron Olivier⁴^ORCID,Hamzaoui Nadim⁵⁶^ORCID,Pasmant Eric⁵⁶^ORCID,Danlos Francois-Xavier⁷⁸⁹^ORCID,Boudou-Rouquette Pascaline⁵¹⁰,Srikaran Arunya¹⁰,Blons Hélène¹¹^ORCID,Guarneri Valentina²¹²^ORCID,Loi Sherene¹³¹⁴^ORCID,André Fabrice¹³^ORCID,Tlemsani Camille⁵¹⁰^ORCID

Affiliation:

1. INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France

2. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

3. Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France

4. Oncogenetic Department, Institut Gustave Roussy, Villejuif, France

5. INSERM U1016, CNRS UMR8104, Université Paris Cité, CARPEM, Institut Cochin, Paris, France

6. Department of Molecular Biology, Fédération de Génétique et Médecine Génomique, Cochin Hospital, Université Paris Cité, APHP Centre, Paris, France

7. Drug Development Department, Gustave Roussy, Villejuif, France

8. INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France

9. Faculté de Médecine, Université Paris Saclay, Gif-sur-Yvette, France

10. Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP Centre, Paris, France

11. Department of Molecular Biology, Fédération de Génétique et Médecine Génomique, European Geoges Pompidou Hospital, Université Paris Cité, APHP Centre, Paris, France

12. Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

13. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

14. The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia

Abstract

A case series evaluating efficacy and safety of immune checkpoint blockade in Li-Fraumeni syndrome

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.24.00139

Reference18 articles.

1. Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes

2. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

3. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

4. p53 Mutations in Human Cancers

5. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas